Parkinson’s disease drug also can curb dementia’s delusions, researchers find
If regulators agree, the drug — a daily pill sold as Nuplazid — could become the first treatment specifically for dementia-related psychosis and the first new medicine for Alzheimer’s in nearly two decades.
A drug that curbs delusions in Parkinson’s patients did the same for people with Alzheimer’s disease and other forms of dementia, according to a study that was stopped early because the benefit seemed clear.
If regulators agree, the drug could become the first treatment specifically for dementia-related psychosis and the first new medicine for Alzheimer’s in nearly two decades.
It targets some of the most troubling symptoms that patients and caregivers face — hallucinations that often lead to anxiety, aggression, and physical and verbal abuse.
The study results were disclosed Wednesday at a conference in San Diego.
“This would be a very important advance,” said one independent expert, Dr. Howard Fillit, chief science officer of the Alzheimer’s Drug Discovery Foundation.
Though the field is focused on finding a cure for dementia and preventing future cases, “there is a huge unmet need for better treatment” for those who have it now, said Maria Carrillo, chief science officer for the Chicago-based Alzheimer’s Association.
The drug is pimavanserin, a daily pill sold as Nuplazid by Acadia Pharmaceuticals Inc. It was approved for Parkinson’s-related psychosis in 2016 and is thought to work by blocking a brain chemical that seems to spur delusions.
About 8 million Americans have dementia. Studies suggest that as many as30% of them develop psychosis.
“It’s terrifying,” said Dr. Jeffrey Cummings of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. “You believe that people might be trying to hurt you. You believe that people are stealing from you. You believe that your spouse is unfaithful to you. Those are the three most common false beliefs.”
He consults for Acadia and helped lead the study, which included about 400 people with dementia and psychosis.
All were given a low dose of the drug for three months. Those who seemed to respond or benefit were then split into two groups. Half continued on the drug. The others were given dummy pills for six months or until they had a relapse or worsening of symptoms. Neither the patients nor their doctors knew who was getting what.
Independent monitors stopped the study when they saw that those on dummy pills were more than twice as likely as those on the drug to relapse or worsen — 28% versus nearly 13%.
There were relatively few serious side effects — 5% in the drug group and 4% in the others. Headaches and urinary tract infections were more common among those on the drug. Two deaths occurred, but study leaders said neither was related to the drug.
Carrillo said the study was small, but the drug’s effect seemed large, and it’s not known whether the federal Food and Drug Administration would want more evidence to approve a new use.
Current anti-psychotic medicines have some major drawbacks and are not approved for dementia patients.
“They’re often used off-label because we have very few other options,” Fillit said.
All carry warnings that they can raise the risk of death in elderly patients, as does Nuplazid.
Cost could be an issue — about $3,000 a month. What patients pay can vary depending on insurance.